Induction of rat liver microsomal drug-metabolizing enzymes by a new sleep inducer 450191-S and plasma levels of 450191-S-metabolites.

Takashi Matsubara, Akira Touchi, Noriko Yamada, Koichi SugenoJournal of Pharmacobio-Dynamics 1986 · DOI

Abstract

Liver microsomal 7-alkoxycoumarin O-dealkylase activities in rats were stimulated by the administration of large doses of 5-[(2-aminoacetamide)methyl]-1-[4-chloro-2-(o-chlorobenzoyl)phenyl ]-N, N-dimethyl-1 H-s-triazole-3-carboxamide hydrochloride dihydrate (450191-S), a new sleep inducer which is a 1H-1,2,4-triazolyl benzophenone derivative. To obtain the correlation between the stimulation or induction of hepatic enzymes and the plasma level of the metabolites of 450191-S, various amounts of 450191-S were administered orally to rats and the metabolites in plasma were determined by high performance liquid chromatography. Plasma concentration-time profiles for metabolites in rats showed the appearance of metabolites in plasma followed by their rapid disappearance from blood when the animals received non-inducing amounts of 450191-S. On the other hand, the profiles of metabolites in rats administered higher amounts of the drug showed very high plasma concentrations of metabolites, especially 8-chloro-6-(2-chlorophenyl)-N-methyl-4H-1,2,4-triazolo [1,5-a] [1,4]benzodiazepine-2-carboxamide (M-2) and 8-chloro-6-(2- chlorophenyl)-N-hydroxymethyl-4H-1,2,4-triazolo [1,5-a] [1,4]benzodiazepine-2-carboxamide (M-A), which were maintained for a long time with slow elimination. These results led to the conclusion that the induction of hepatic drug-metabolizing enzymes is closely correlated with the high plasma concentrations of metabolites and their prolonged existence in plasma.

Introduction

Many drugs, particularly benzodiazepines and their derivatives, are known to be "enzyme inducers." They stimulate the liver to produce more microsomal enzymes, such as Cytochrome P-450, which can accelerate the metabolism of the drug itself or other co-administered medications. This phenomenon is a significant concern for drug-drug interactions and long-term therapeutic efficacy.

While the sleep inducer 450191-S (a triazolyl benzophenone derivative) was known to induce these enzymes at high doses, the specific pharmacokinetic trigger remained unknown. This study investigates the relationship between the dosage of 450191-S, the resulting plasma levels of its metabolites, and the induction of hepatic drug-metabolizing enzymes in rats.

Methods

The researchers administered oral doses of 450191-S to adult male rats, ranging from non-inducing (50–100 mg/kg) to inducing (200–600 mg/kg) levels. High-Performance Liquid Chromatography (HPLC) was employed to track the concentration-time profiles of six distinct metabolites: M-1, M-2, M-3, M-4, M-A, and M-D.

Metabolic pathway of 450191-S in rats.

To measure enzyme induction, liver microsomes were analyzed for 7-alkoxycoumarin O-dealkylase activity, a sensitive marker for specific Cytochrome P-450 enzymes. A critical methodological step involved using an alkaline solution ($0.1\text{ M Na}_2\text{CO}_3$) during sample preparation to stabilize metabolites M-D and M-A by converting them into M-2 and M-3, respectively, for accurate quantification.

Results and Key Insights

The Saturation Threshold and Metabolite Persistence

The study revealed that enzyme induction is not a simple linear response but is tied to a metabolic threshold. At low doses (50–100 mg/kg), metabolites appeared and were rapidly cleared from the plasma. However, at doses of 200 mg/kg and above, the elimination rate slowed significantly, suggesting that the metabolic pathways for clearance become saturated.

Plasma concentration-time profiles of 450191-S metabolites at various oral doses.

In the high-dose group (600 mg/kg), the combined plasma levels of M-2 and M-D remained above $5\text{ }\mu\text{g/ml}$ even 6 hours after administration. In contrast, these metabolites were undetectable within 4 hours in the low-dose groups. This prolonged existence in the plasma perfectly correlated with the spike in hepatic enzyme activity.

Identifying Active Inducers

By testing individual metabolites in mice, the researchers identified M-1 and M-2 as potent enzyme inducers. In mice, direct administration of M-2 increased 7-methoxycoumarin O-demethylase activity by nearly 70% compared to controls. Conversely, metabolites M-A and M-3 showed little to no inducing effect.

Enzyme Stimulation Patterns

High doses (600 mg/kg) of 450191-S more than doubled the activity of 7-ethoxycoumarin O-deethylase, increasing from $1.29 \pm 0.10$ to $2.77 \pm 0.22\text{ nmol/min/mg}$ protein. This induction pattern closely resembles that of phenobarbital, a classic reference inducer for the Cytochrome P-450 system.

Discussion

The findings conclude that the induction of hepatic drug-metabolizing enzymes by 450191-S is closely correlated with high plasma concentrations and the prolonged presence of specific metabolites, particularly M-1 and M-2.

While these results provide a clear pharmacokinetic link, some limitations remain. The study was conducted in rodent models; human metabolic rates and induction thresholds may differ. Furthermore, the exact molecular signaling pathways that translate high metabolite levels into increased gene expression were not explored in this 1986 study. Future research into the structural-activity relationships of triazolo-benzodiazepines could further clarify their inducing potency.

Summary updated

Abstract

Liver microsomal 7-alkoxycoumarin O-dealkylase activities in rats were stimulated by the administration of large doses of 5-[(2-aminoacetamide)methyl]-1-[4-chloro-2-(o-chlorobenzoyl)phenyl ]-N, N-dimethyl-1 H-s-triazole-3-carboxamide hydrochloride dihydrate (450191-S), a new sleep inducer which is a 1H-1,2,4-triazolyl benzophenone derivative. To obtain the correlation between the stimulation or induction of hepatic enzymes and the plasma level of the metabolites of 450191-S, various amounts of 450191-S were administered orally to rats and the metabolites in plasma were determined by high performance liquid chromatography. Plasma concentration-time profiles for metabolites in rats showed the appearance of metabolites in plasma followed by their rapid disappearance from blood when the animals received non-inducing amounts of 450191-S. On the other hand, the profiles of metabolites in rats administered higher amounts of the drug showed very high plasma concentrations of metabolites, especially 8-chloro-6-(2-chlorophenyl)-N-methyl-4H-1,2,4-triazolo [1,5-a] [1,4]benzodiazepine-2-carboxamide (M-2) and 8-chloro-6-(2- chlorophenyl)-N-hydroxymethyl-4H-1,2,4-triazolo [1,5-a] [1,4]benzodiazepine-2-carboxamide (M-A), which were maintained for a long time with slow elimination. These results led to the conclusion that the induction of hepatic drug-metabolizing enzymes is closely correlated with the high plasma concentrations of metabolites and their prolonged existence in plasma.
BibTeX
@article{matsubara1986induction,
  author = {Takashi Matsubara and Akira Touchi and Noriko Yamada and Koichi SUGENO},
  title = {{Induction of rat liver microsomal drug-metabolizing enzymes by a new sleep inducer 450191-S and plasma levels of 450191-S-metabolites.}},
  journal = {Journal of Pharmacobio-Dynamics},
  year = {1986},
  doi = {10.1248/bpb1978.9.249},
}
Figure